Regarding MDI regimens, the use of modern ultra–long-acting insulin analogues along with carbohydrate counting help reduce the risk of hypoglycemia; patients on CSII therapy also have important tools to prevent this complication (9,15). Here, INS is linked to Hypoglycemia.